Recent revelations of positive doping tests for nearly two dozen Chinese swimmers have ignited a heated dispute between the World Anti-Doping Agency (WADA) and the U.S. Anti-Doping Agency. The controversy stemmed from WADA's decision to clear 23 Chinese swimmers who had tested positive for a banned heart medication to compete at the Tokyo Olympics in 2021, citing contamination of samples as the reason.
WADA defended its process, stating that it acted in good faith and followed due process in accepting the Chinese explanation for the positive tests. However, the CEO of the U.S. Anti-Doping Agency criticized WADA for allegedly failing to enforce global anti-doping rules uniformly.
